Skip to main content
SpringerLink
Log in

Hepatic, Pancreatic and Biliary Cancers

  • Chapter
  • First Online:
Translation and Its Regulation in Cancer Biology and Medicine

Abstract

Hepato-pancreato-biliary (HPB) cancers, which are among the most lethal of malignancies, often show alterations in the expression of components of the translation machinery and the regulation of their function. Changes in translation initiation factors, elongation factors and ribosomal proteins and RNA have been demonstrated across the range of HPB cancers. Viruses that are causative for hepatocellular carcinoma (HCC) have been shown to directly interact with the translation apparatus. All forms of HPB cancer, including not only HCC but also cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC), have been associated with altered signal transduction pathways involved in the control of translation. Understanding the mechanisms accounting for the dysregulation of translation in HPB cancers has led to the identification of novel biomarkers, prognostic indicators, and preventive and chemotherapeutic treatment strategies. Further developments in this area have the potential to improve the outcome for these devastating disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adesso L, Calabretta S, Barbagallo F, Capurso G, Pilozzi E, Geremia R, Delle Fave G, Sette C (2012) Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 32:2848–2857

    PubMed  Google Scholar 

  • Altman JK, Glaser H, Sassano A, Joshi S, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Tallman MS, Platanias LC (2010) Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses. Mol Pharmacol 78:778–784

    PubMed  CAS  PubMed Central  Google Scholar 

  • Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS (2010) Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 51:1401–1409

    PubMed  PubMed Central  Google Scholar 

  • Aufiero B, Schneider RJ (1990) The hepatitis B virus X-gene product trans-activates both RNA polymerase II and III promoters. EMBO J 9:497–504

    PubMed  CAS  PubMed Central  Google Scholar 

  • Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, Rao PH, Ruggero D (2008) Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 456:971–975

    PubMed  CAS  PubMed Central  Google Scholar 

  • Benelli D, Cialfi S, Pinzaglia M, Talora C, Londei P (2012) The translation factor eIF6 is a Notch-dependent regulator of cell migration and invasion. PLoS ONE 7:e32047

    PubMed  CAS  PubMed Central  Google Scholar 

  • Bhat M, Sonenberg N, Gores GJ (2013) The mTOR pathway in hepatic malignancies. Hepatology 58:810–818

    PubMed  CAS  PubMed Central  Google Scholar 

  • Blechacz BR, Gores GJ (2008) Cholangiocarcinoma. Clin Liver Dis 12:131–150

    PubMed  Google Scholar 

  • Boberg KM, Schrumpf E, Bergquist A, Broome U, Pares A, Remotti H, Schjolberg A, Spurkland A, Clausen OP (2000) Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol 32:374–380

    PubMed  CAS  Google Scholar 

  • Braun L, Mikumo R, Fausto N (1989) Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-myc and p53 at different stages of oval cell transformation. Cancer Res 49:1554–1561

    PubMed  CAS  Google Scholar 

  • Browne GJ, Proud CG (2002) Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem 269:5360–5368

    PubMed  CAS  Google Scholar 

  • Buitrago-Molina LE, Pothiraju D, Lamle J, Marhenke S, Kossatz U, Breuhahn K, Manns MP, Malek N, Vogel A (2009) Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage. Hepatology 50:500–509

    PubMed  CAS  Google Scholar 

  • Cao H, Zhu Q, Huang J, Li B, Zhang S, Yao W, Zhang Y (2009) Regulation and functional role of eEF1A2 in pancreatic carcinoma. Biochem Biophys Res Commun 380:11–16

    PubMed  CAS  Google Scholar 

  • Center MM, Jemal A (2011) International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 20:2362–2368

    PubMed  Google Scholar 

  • Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A et al (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59:561–574

    PubMed  CAS  Google Scholar 

  • Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM (2009) The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 15:660–667

    PubMed  CAS  Google Scholar 

  • Cinar P, Tempero MA (2012) Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J 18:653–664

    PubMed  CAS  Google Scholar 

  • Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D et al (2012) A central role for RAF-->MEK-->ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2:685–693

    PubMed  CAS  PubMed Central  Google Scholar 

  • Colman H, Le Berre-Scoul C, Hernandez C, Pierredon S, Bihouee A, Houlgatte R, Vagner S, Rosenberg AR, Feray C (2013) Genome-wide analysis of host mRNA translation during hepatitis C virus infection. J Virol 87:6668–6677

    PubMed  CAS  PubMed Central  Google Scholar 

  • De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189–3199

    PubMed  CAS  Google Scholar 

  • DeHaan RD, Kipp BR, Smyrk TC, Abraham SC, Roberts LR, Halling KC (2007) An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum Pathol 38:491–499

    PubMed  CAS  Google Scholar 

  • Doldan A, Chandramouli A, Shanas R, Bhattacharyya A, Cunningham JT, Nelson MA, Shi J (2008) Loss of the eukaryotic initiation factor 3f in pancreatic cancer. Mol Carcinog 47:235–244

    PubMed  CAS  PubMed Central  Google Scholar 

  • Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T (2006) The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 49:138–151

    PubMed  CAS  Google Scholar 

  • Eng CP, Sehgal SN, Vezina C (1984) Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 37:1231–1237

    CAS  Google Scholar 

  • Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7:e38

    PubMed  Google Scholar 

  • Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M et al (2012) Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 152:43–49

    Google Scholar 

  • Gandin V, Miluzio A, Barbieri AM, Beugnet A, Kiyokawa H, Marchisio PC, Biffo S (2008) Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation. Nature 455:684–688

    PubMed  CAS  PubMed Central  Google Scholar 

  • Garcia-Martinez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416:375–385

    PubMed  CAS  Google Scholar 

  • George A, Panda S, Kudmulwar D, Chhatbar SP, Nayak SC, Krishnan HH (2012) Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation. J Biol Chem 287:5042–5058

    PubMed  CAS  PubMed Central  Google Scholar 

  • Gonda TA, Glick MP, Sethi A, Poneros JM, Palmas W, Iqbal S, Gonzalez S, Nandula SV, Emond JC, Brown RS et al (2012) Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest Endosc 75:74–79

    PubMed  Google Scholar 

  • Grassi G, Scaggiante B, Farra R, Dapas B, Agostini F, Baiz D, Rosso N, Tiribelli C (2007) The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. Biochimie 89:1544–1552

    PubMed  CAS  Google Scholar 

  • Gross SR, Kinzy TG (2005) Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat Struct Mol Biol 12:772–778

    PubMed  CAS  Google Scholar 

  • Gruppuso PA, Tsai SW, Boylan JM, Sanders JA (2008) Hepatic translation control in the late-gestation fetal rat. Am J Physiol Regul Integr Comp Physiol 295:R558–R567

    PubMed  CAS  PubMed Central  Google Scholar 

  • Gruppuso PA, Boylan JM, Sanders JA (2011) The physiology and pathophysiology of rapamycin resistance: implications for cancer. Cell Cycle 10:1050–1058

    PubMed  CAS  PubMed Central  Google Scholar 

  • Grzmil M, Morin P Jr, Lino MM, Merlo A, Frank S, Wang Y, Moncayo G, Hemmings BA (2011) MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma. Cancer Res 71:2392–2402

    PubMed  CAS  Google Scholar 

  • Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. SciSignal 2:e24

    Google Scholar 

  • Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, Terracciano L, Heim MH, Ruegg MA, Hall MN (2012) Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 15:725–738

    PubMed  CAS  Google Scholar 

  • He Y, Tan SL, Tareen SU, Vijaysri S, Langland JO, Jacobs BL, Katze MG (2001) Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A. J Virol 75:5090–5098

    PubMed  CAS  PubMed Central  Google Scholar 

  • He C, Jiang H, Geng S, Sheng H, Shen X, Zhang X, Zhu S, Chen X, Yang C, Gao H (2012) Expression of c-Myc and Fas correlates with perineural invasion of pancreatic cancer. Int J Clin Exp Pathol 5:339–346

    PubMed  CAS  PubMed Central  Google Scholar 

  • Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R, Filipits M (2007) Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 13:4795–4799

    PubMed  CAS  Google Scholar 

  • Hertz MI, Landry DM, Willis AE, Luo G, Thompson SR (2013) Ribosomal protein S25 dependency reveals a common mechanism for diverse internal ribosome entry sites and ribosome shunting. Mol Cell Biol 33:1016–1026

    PubMed  CAS  PubMed Central  Google Scholar 

  • Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, Abraham RT, Lawrence JC Jr, Houghton PJ (1998) Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 54:815–824

    PubMed  CAS  Google Scholar 

  • Huang JY, Su WC, Jeng KS, Chang TH, Lai MM (2012) Attenuation of 40S ribosomal subunit abundance differentially affects host and HCV translation and suppresses HCV replication. PLoS Pathog 8:e1002766

    PubMed  CAS  PubMed Central  Google Scholar 

  • Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J et al (1998) Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27:951–958

    PubMed  CAS  Google Scholar 

  • Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122–1128

    PubMed  CAS  Google Scholar 

  • Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806

    PubMed  CAS  PubMed Central  Google Scholar 

  • Kao CF, Chen SY, Lee YH (2004) Activation of RNA polymerase I transcription by hepatitis C virus core protein. J Biomed Sci 11:72–94

    PubMed  CAS  Google Scholar 

  • Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, Conner EA, Factor VM, Roskams T, Thorgeirsson SS (2009) Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 69:2775–2782

    PubMed  CAS  PubMed Central  Google Scholar 

  • Knudsen SM, Frydenberg J, Clark BF, Leffers H (1993) Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha. Eur J Biochem 215:549–554

    PubMed  CAS  Google Scholar 

  • Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ (2005) Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128:2054–2065

    PubMed  CAS  Google Scholar 

  • Korc M (2003) Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2:8

    PubMed  CAS  PubMed Central  Google Scholar 

  • Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS et al (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335:1638–1643

    PubMed  CAS  PubMed Central  Google Scholar 

  • Lamming DW, Demirkan G, Boylan JM, Mihaylova MM, Peng T, Ferreira J, Neretti N, Salomon A, Sabatini DM, Gruppuso PA (2013) Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2). FASEB J 28:300–315

    PubMed  Google Scholar 

  • Landry DM, Hertz MI, Thompson SR (2009) RPS25 is essential for translation initiation by the dicistroviridae and hepatitis C viral IRESs. Genes Dev 23:2753–2764

    PubMed  CAS  PubMed Central  Google Scholar 

  • Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z et al (2006) A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12:410–416

    PubMed  CAS  Google Scholar 

  • Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM et al (2010a) The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A 107:8248–8253

    CAS  Google Scholar 

  • Lee NP, Tsang FH, Shek FH, Mao M, Dai H, Zhang C, Dong S, Guan XY, Poon RT, Luk JM (2010b) Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Int J Cancer 127:968–976

    CAS  Google Scholar 

  • Lee D, Do IG, Choi K, Sung CO, Jang KT, Choi D, Heo JS, Choi SH, Kim J, Park JY et al (2012) The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol 25:131–139

    PubMed  CAS  Google Scholar 

  • Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ, Tan CJ, Huang XY, Ke AW, Dai Z, Fan J et al (2012) Activation of PI3K/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS ONE 7:e33379

    PubMed  CAS  PubMed Central  Google Scholar 

  • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    PubMed  CAS  Google Scholar 

  • Lowenfels AB, Maisonneuve P (2005) Risk factors for pancreatic cancer. J Cell Biochem 95:649–656

    PubMed  CAS  Google Scholar 

  • Lowes K, Brennan B, Yeoh G, Olynyk J (1999) Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 154:537–541

    PubMed  CAS  PubMed Central  Google Scholar 

  • Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E, Kakolyris S (2011) Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology 81:259–272

    PubMed  CAS  Google Scholar 

  • McCahill A, Warwicker J, Bolger GB, Houslay MD, Yarwood SJ (2002) The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol Pharmacol 62:1261–1273

    PubMed  CAS  Google Scholar 

  • McGlynn KA, London WT (2011) The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 15:223–243, vii–x

    PubMed  PubMed Central  Google Scholar 

  • Menakongka A, Suthiphongchai T (2010) Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol 16:713–722

    PubMed  CAS  PubMed Central  Google Scholar 

  • Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT et al (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 105:10853–10858

    PubMed  CAS  PubMed Central  Google Scholar 

  • Mishra R, Miyamoto M, Yoshioka T, Ishikawa K, Matsumura Y, Shoji Y, Ichinokawa K, Itoh T, Shichinohe T, Hirano S et al (2009) Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo. Int J Oncol 34:1231–1240

    PubMed  CAS  Google Scholar 

  • Narla A, Ebert BL (2010) Ribosomopathies: human disorders of ribosome dysfunction. Blood 115:3196–3205

    PubMed  CAS  PubMed Central  Google Scholar 

  • Nilsson J, Sengupta J, Frank J, Nissen P (2004) Regulation of eukaryotic translation by the RACK1 protein: a platform for signalling molecules on the ribosome. EMBO Rep 5:1137–1141

    PubMed  CAS  PubMed Central  Google Scholar 

  • O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500–1508

    PubMed  PubMed Central  Google Scholar 

  • Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A (1994) Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 9:462–467

    PubMed  CAS  Google Scholar 

  • Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J (2003) PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 38:1242–1249

    PubMed  CAS  Google Scholar 

  • Pestova TV, Kolupaeva VG, Lomakin IB, Pilipenko EV, Shatsky IN, Agol VI, Hellen CU (2001) Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci U S A 98:7029–7036

    PubMed  CAS  PubMed Central  Google Scholar 

  • Pineiro D, Martinez-Salas E (2012) RNA structural elements of hepatitis C virus controlling viral RNA translation and the implications for viral pathogenesis. Viruses 4:2233–2250

    PubMed  CAS  PubMed Central  Google Scholar 

  • Raychaudhuri S, Fontanes V, Barat B, Dasgupta A (2009) Activation of ribosomal RNA transcription by hepatitis C virus involves upstream binding factor phosphorylation via induction of cyclin D1. Cancer Res 69:2057–2064

    PubMed  CAS  PubMed Central  Google Scholar 

  • Rini BI (2010) New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 16:1348–1354

    PubMed  CAS  Google Scholar 

  • Rizell M, Andersson M, Cahlin C, Hafstrom L, Olausson M, Lindner P (2008) Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 13:66–70

    PubMed  CAS  Google Scholar 

  • Roskams T (2006) Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25:3818–3822

    PubMed  CAS  Google Scholar 

  • Rosso P, Cortesina G, Sanvito F, Donadini A, Di Benedetto B, Biffo S, Marchisio PC (2004) Overexpression of p27BBP in head and neck carcinomas and their lymph node metastases. Head Neck 26:408–417

    PubMed  Google Scholar 

  • Ruan Y, Sun L, Hao Y, Wang L, Xu J, Zhang W, Xie J, Guo L, Zhou L, Yun X, et al. (2012) Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest 122:2554–2566

    PubMed  CAS  PubMed Central  Google Scholar 

  • Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10:484–486

    PubMed  CAS  Google Scholar 

  • Sanders JA, Brilliant KE, Clift D, Patel A, Cerretti B, Claro P, Mills DR, Hixson DC, Gruppuso PA (2012) The inhibitory effect of rapamycin on the oval cell response and development of preneoplastic foci in the rat. Exp Mol Pathol 93:40–49

    PubMed  CAS  PubMed Central  Google Scholar 

  • Sanvito F, Vivoli F, Gambini S, Santambrogio G, Catena M, Viale E, Veglia F, Donadini A, Biffo S, Marchisio PC (2000) Expression of a highly conserved protein, p27BBP, during the progression of human colorectal cancer. Cancer Res 60:510–516

    PubMed  CAS  Google Scholar 

  • Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101

    PubMed  CAS  Google Scholar 

  • Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159–168

    PubMed  CAS  Google Scholar 

  • Sauerland C, Engelking C, Wickham R, Pearlstone DB (2009) Cancers of the pancreas and hepatobiliary system. Semin Oncol Nurs 25:76–92

    PubMed  Google Scholar 

  • Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R et al (2010) A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 10:190

    PubMed  PubMed Central  Google Scholar 

  • Schoniger-Hekele M, Muller C (2010) Pilot study: rapamycin in advanced hepatocellular carcinoma. Aliment Pharmacol Ther 32:763–768

    PubMed  CAS  Google Scholar 

  • Schuhmacher M, Staege MS, Pajic A, Polack A, Weidle UH, Bornkamm GW, Eick D, Kohlhuber F (1999) Control of cell growth by c-Myc in the absence of cell division. Curr Biol 9:1255–1258

    PubMed  CAS  Google Scholar 

  • Sengupta J, Nilsson J, Gursky R, Spahn CM, Nissen P, Frank J (2004) Identification of the versatile scaffold protein RACK1 on the eukaryotic ribosome by cryo-EM. Nat Struct Mol Biol 11:957–962

    PubMed  CAS  Google Scholar 

  • Shek FH, Fatima S, Lee NP (2012) Implications of the use of eukaryotic translation initiation factor 5A (eIF5A) for prognosis and treatment of hepatocellular carcinoma. Int J Hepatol 2012:760928

    PubMed  PubMed Central  Google Scholar 

  • Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C, Verma A (2012) Alterations in the ribosomal machinery in cancer and hematologic disorders. J Hematol Oncol 5:32

    PubMed  CAS  PubMed Central  Google Scholar 

  • Shi J, Kahle A, Hershey JW, Honchak BM, Warneke JA, Leong SP, Nelson MA (2006) Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells. Oncogene 25:4923–4936

    PubMed  CAS  Google Scholar 

  • Shirouzu Y, Ryschich E, Salnikova O, Kerkadze V, Schmidt J, Engelmann G (2010) Rapamycin inhibits proliferation and migration of hepatoma cells in vitro. J Surg Res 159:705–713

    PubMed  CAS  Google Scholar 

  • Shuda M, Kondoh N, Tanaka K, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T et al (2000) Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res 20:2489–2494

    PubMed  CAS  Google Scholar 

  • Silvera D, Formenti SC, Schneider RJ (2010) Translational control in cancer. Nat Rev Cancer 10:254–266

    PubMed  CAS  Google Scholar 

  • Sinha S, Neal GE, Legg RF, Watson JV, Pearson C (1989) The expression of c-myc related to the proliferation and transformation of rat liver-derived epithelial cells. Br J Cancer 59:674–676

    PubMed  CAS  PubMed Central  Google Scholar 

  • Song MJ, Jung CK, Park CH, Hur W, Choi JE, Bae SH, Choi JY, Choi SW, Han NI, Yoon SK (2011) RPL36 as a prognostic marker in hepatocellular carcinoma. Pathol Int 61:638–644

    PubMed  CAS  Google Scholar 

  • Soong RS, Yu MC, Chan KM, Chou HS, Wu TJ, Lee CF, Wu TH, Lee WC (2011) Analysis of the recurrence risk factors for the patients with hepatocellular carcinoma meeting University of California San Francisco criteria after curative hepatectomy. World J Surg Oncol 9:9

    PubMed  PubMed Central  Google Scholar 

  • Stanners CP, Adams ME, Harkins JL, Pollard JW (1979) Transformed cells have lost control of ribosome number through their growth cycle. J Cell Physiol 100:127–138

    PubMed  CAS  Google Scholar 

  • Stelzer MK, Pitot HC, Liem A, Lee D, Kennedy GD, Lambert PF (2010) Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila) 3:1542–1551

    CAS  Google Scholar 

  • Stumpf CR, Ruggero D (2011) The cancerous translation apparatus. Curr Opin Genet Dev 21:474–483

    PubMed  CAS  PubMed Central  Google Scholar 

  • Subbiah V, Trent JC, Kurzrock R (2010) Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol 28:e415

    PubMed  Google Scholar 

  • Talapatra S, Wagner JD, Thompson CB (2002) Elongation factor-1 alpha is a selective regulator of growth factor withdrawal and ER stress-induced apoptosis. Cell Death Differ 9:856–861

    PubMed  CAS  Google Scholar 

  • Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, Lau SH, Li Y, Guan XY (2010) Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology 51:1255–1263

    PubMed  CAS  Google Scholar 

  • Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284:8023–8032

    PubMed  CAS  PubMed Central  Google Scholar 

  • Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, Shimizu Y, Itamoto T, Arihiro K, Okajima M et al (2005) Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol 27:973–980

    PubMed  CAS  Google Scholar 

  • Topisirovic I, Sonenberg N (2011) mRNA translation and energy metabolism in cancer: the role of the MAPK and mTORC1 pathways. Cold Spring Harb Symp Quant Biol 76:355–367

    PubMed  CAS  Google Scholar 

  • Trevisani F, Cantarini MC, Wands JR, Bernardi M (2008) Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 29:1299–1305

    PubMed  CAS  Google Scholar 

  • Vasilieva LE, Papadhimitriou SI, Dourakis SP (2012) Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 11:349–359

    PubMed  Google Scholar 

  • Vezina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28:721–726

    CAS  Google Scholar 

  • Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M et al (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135:1972–1983 (1983)

    PubMed  CAS  PubMed Central  Google Scholar 

  • Voravud N, Foster CS, Gilbertson JA, Sikora K, Waxman J (1989) Oncogene expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol 20:1163–1168

    PubMed  CAS  Google Scholar 

  • Wang X, Proud CG (2011) mTORC1 signaling: what we still don’t know. J Mol Cell Biol 3:206–220

    PubMed  CAS  Google Scholar 

  • Wang HD, Trivedi A, Johnson DL (1998) Regulation of RNA polymerase I-dependent promoters by the hepatitis B virus X protein via activated Ras and TATA-binding protein. Mol Cell Biol 18:7086–7094

    PubMed  CAS  PubMed Central  Google Scholar 

  • Wang W, Jia WD, Xu GL, Wang ZH, Li JS, Ma JL, Ge YS, Xie SX, Yu JH (2009) Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma. Dig Dis Sci 54:2128–2136

    PubMed  CAS  Google Scholar 

  • Wang XL, Cai HP, Ge JH, Su XF (2012) Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J Gastroenterol 18:2540–2544

    PubMed  CAS  PubMed Central  Google Scholar 

  • Wang YW, Lin KT, Chen SC, Gu DL, Chen CF, Tu PH, Jou YS (2013) Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma. Hepatology 58:239–250

    PubMed  CAS  Google Scholar 

  • Wehbe H, Henson R, Lang M, Meng F, Patel T (2006) Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes. J Pharmacol Exp Ther 319:1153–1161

    PubMed  CAS  Google Scholar 

  • Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J et al (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21:3232–3237

    PubMed  CAS  PubMed Central  Google Scholar 

  • Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29:4989–5005

    PubMed  CAS  Google Scholar 

  • Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

    PubMed  CAS  Google Scholar 

  • Xu C, Hu DM, Zhu Q (2013) eEF1A2 promotes cell migration, invasion and metastasis in pancreatic cancer by upregulating MMP-9 expression through Akt activation. Clin Exp Metastasis 30:933–944

    PubMed  Google Scholar 

  • Yachimski P, Pratt DS (2008) Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 42:178–190

    PubMed  Google Scholar 

  • Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX et al (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68:1451–1461

    PubMed  CAS  Google Scholar 

  • Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, Sun HC, Qiu SJ, Yu B, Gao Q et al (2008) Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 14:3850–3859

    PubMed  CAS  Google Scholar 

  • Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B et al (2010) High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59:953–962

    PubMed  CAS  Google Scholar 

  • Yu Y, Ji H, Doudna JA, Leary JA (2005) Mass spectrometric analysis of the human 40S ribosomal subunit: native and HCV IRES-bound complexes. Protein Sci 14:1438–1446

    PubMed  CAS  PubMed Central  Google Scholar 

  • Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D et al (2011) Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117:5094–5102

    PubMed  CAS  PubMed Central  Google Scholar 

  • Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21–35

    PubMed  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Brown University and Rhode Island Hospital, Providence, RI, USA

    Jennifer A. Sanders & Philip A. Gruppuso

Authors
  1. Jennifer A. Sanders
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip A. Gruppuso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip A. Gruppuso .

Editor information

Editors and Affiliations

  1. Surgery, McGill University, Montreal, Québec, Canada

    Armen Parsyan

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Sanders, J., Gruppuso, P. (2014). Hepatic, Pancreatic and Biliary Cancers. In: Parsyan, A. (eds) Translation and Its Regulation in Cancer Biology and Medicine. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9078-9_30

Download citation

Publish with us

Policies and ethics

Search

Navigation